Trial Profile
Apatinib combined with radiotherapy to improve clinical curative effect in the treatment of advanced lung cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Jan 2018 New trial record